Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (433) 433
binding, competitive (341) 341
humans (244) 244
rats (224) 224
male (202) 202
index medicus (187) 187
pharmacology & pharmacy (166) 166
kinetics (109) 109
competitive acid blocker (108) 108
biochemistry & molecular biology (106) 106
dose-response relationship, drug (92) 92
binding, competitive - drug effects (90) 90
female (90) 90
mice (90) 90
neurosciences (89) 89
in vitro techniques (88) 88
proton pump inhibitors (86) 86
gastroenterology & hepatology (80) 80
vonoprazan (74) 74
binding sites (71) 71
calcium channel blockers - pharmacology (70) 70
molecular sequence data (66) 66
amino acid sequence (65) 65
radioligand assay (62) 62
rats, sprague-dawley (62) 62
structure-activity relationship (61) 61
potassium-competitive acid blocker (54) 54
binding (53) 53
brain - metabolism (52) 52
helicobacter pylori (52) 52
ligands (49) 49
research (47) 47
cells, cultured (45) 45
calcium - metabolism (43) 43
calcium channel blockers - metabolism (43) 43
article (41) 41
patch-clamp techniques (41) 41
proton pump inhibitors - therapeutic use (41) 41
analysis (38) 38
excitatory amino acid antagonists - pharmacology (37) 37
physiology (37) 37
protein binding (37) 37
rat-brain (37) 37
receptors (37) 37
middle aged (36) 36
proton pump inhibitor (35) 35
receptors, n-methyl-d-aspartate - antagonists & inhibitors (35) 35
molecular structure (34) 34
proteins (34) 34
chemistry, medicinal (32) 32
gastroesophageal reflux (32) 32
gastroesophageal-reflux disease (32) 32
guinea pigs (32) 32
lansoprazole (32) 32
membrane potentials - drug effects (32) 32
pharmacology (32) 32
rats, wistar (32) 32
tritium (32) 32
cell membrane - metabolism (31) 31
esomeprazole (31) 31
neurons - drug effects (31) 31
receptor (31) 31
brain (30) 30
cell line (30) 30
inhibition (30) 30
drug interactions (29) 29
adult (28) 28
gastroesophageal reflux disease (28) 28
helicobacter infections - drug therapy (28) 28
mutation (28) 28
pyrroles - therapeutic use (28) 28
treatment outcome (28) 28
triple therapy (28) 28
aged (27) 27
multidisciplinary sciences (27) 27
peptides - pharmacology (27) 27
physiological aspects (27) 27
sulfonamides - therapeutic use (27) 27
brain - drug effects (26) 26
cricetinae (26) 26
enzyme inhibitors - pharmacology (26) 26
expression (26) 26
glutamate (26) 26
stereoisomerism (26) 26
therapy (26) 26
transfection (26) 26
calcium (25) 25
cerebral cortex - metabolism (25) 25
erosive esophagitis (25) 25
models, molecular (25) 25
research article (25) 25
antacids (24) 24
clarithromycin (24) 24
esophagitis (24) 24
infection (24) 24
omeprazole (24) 24
pharmacokinetics (24) 24
potassium (24) 24
3-pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-phenyl (23) 23
binding, competitive - physiology (23) 23
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (726) 726
Japanese (4) 4
Russian (3) 3
German (1) 1
Korean (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases
by Inatomi, Nobuhiro and Matsukawa, Jun and Sakurai, Yuuichi and Otake, Kazuyoshi
Pharmacology and Therapeutics, ISSN 0163-7258, 12/2016, Volume 168, pp. 12 - 22
Acid-related diseases (ARDs), such as peptic ulcers and gastroesophageal reflux disease, represent a major health-care concern. Some major milestones in our... 
Peptic ulcer | Gastric acid secretion | Potassium-competitive acid blocker | Acid-related diseases | H2 receptor | Proton pump inhibitor | receptor | PROTON-PUMP INHIBITOR | RANDOMIZED CLINICAL-TRIAL | GASTRIC H+/K+-ATPASE | H-2 receptor | B RECEPTOR ANTAGONIST | PARIETAL-CELLS | GASTROESOPHAGEAL-REFLUX DISEASE | HELICOBACTER-PYLORI ERADICATION | IN-VIVO | HEALTHY MALE-SUBJECTS | PHARMACOLOGY & PHARMACY | DUODENAL-ULCER PATIENTS | Potassium - metabolism | Proton Pump Inhibitors - adverse effects | Proton Pump Inhibitors - pharmacology | Histamine H2 Antagonists - pharmacology | Gastroesophageal Reflux - physiopathology | Humans | Helicobacter Infections - complications | Gastric Acid - secretion | Gastrointestinal Agents - pharmacology | Animals | Helicobacter Infections - drug therapy | Drug Design | Peptic Ulcer - physiopathology | Gastrointestinal Agents - adverse effects | Helicobacter pylori - isolation & purification | Gastroesophageal Reflux - drug therapy | Peptic Ulcer - drug therapy | Gastroesophageal reflux | Care and treatment | Health aspects | Antacids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa
by Matsukawa, Jun and Kogame, Akifumi and Tagawa, Yoshihiko and Inatomi, Nobuhiro
Digestive Diseases and Sciences, ISSN 0163-2116, 7/2016, Volume 61, Issue 7, pp. 1888 - 1894
Vonoprazan fumarate (TAK-438) is a novel potassium-competitive acid blocker that appears to exert a longer/more potent antisecretory effect than lansoprazole... 
Biochemistry, general | Potassium-competitive acid blocker | Vonoprazan | Medicine & Public Health | Rat | Hepatology | Gastric mucosa | Gastroesophageal reflux disease | TAK-438 | Gastroenterology | Oncology | Transplant Surgery | LANSOPRAZOLE | SAFETY | PROTON PUMP INHIBITORS | PHARMACODYNAMICS | DISEASES | PHARMACOKINETICS | TOLERABILITY | SECRETION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | Autoradiography | Animals | Proton Pump Inhibitors - pharmacokinetics | Pyrroles - pharmacokinetics | Rats | Male | Tritium | Gastric Mucosa - metabolism | Sulfonamides - pharmacokinetics | Gastroesophageal reflux | Antacids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children
by Kusano, Chika and Gotoda, Takuji and Suzuki, Sho and Ikehara, Hisatomo and Moriyama, Mitsuhiko
Journal of Gastroenterology, ISSN 0944-1174, 6/2018, Volume 53, Issue 6, pp. 718 - 724
Helicobacter pylori infection is a risk factor for gastric cancer, and it has been reported that eradication of H. pylori is effective for preventing such... 
Potassium-competitive acid blocker | Medicine & Public Health | Helicobacter pylori | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Children | Surgical Oncology | Proton Pump Inhibitors - adverse effects | Prospective Studies | Clarithromycin - adverse effects | Humans | Helicobacter pylori - drug effects | Male | Treatment Outcome | Clarithromycin - therapeutic use | Proton Pump Inhibitors - therapeutic use | Anti-Bacterial Agents - therapeutic use | Sulfonamides - therapeutic use | Helicobacter Infections - drug therapy | Adolescent | Amoxicillin - therapeutic use | Pyrroles - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Female | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Drug Therapy, Combination | Pyrroles - therapeutic use | Breath Tests - methods | Prevention | Urea | Antihistamines | Enzymes | Helicobacter infections | High schools | Junior high school students | Antibacterial agents | Antacids | Cancer | Confidence intervals | Urine | Clarithromycin | Vomiting | Hypersensitivity | Amoxicillin | Potassium | Stomach cancer | Gastric cancer | Enzyme-linked immunosorbent assay
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux
by Akiyama, Junichi and Hosaka, Hiroko and Kuribayashi, Shiko and Moriyasu, Shiori and Hisada, Yuya and Okubo, Hidetaka and Watanabe, Kazuhiro and Imbe, Koh and Nagata, Naoyoshi and Kojima, Yasushi and Yokoi, Chizu and Uemura, Naomi and Shimoyama, Yasuyuki and Kawamura, Osamu and Yamada, Masanobu and Kusano, Motoyasu
Digestion, ISSN 0012-2823, 2019, pp. 1 - 10
We evaluated the efficacy of vonoprazan (VPZ), a novel potassium-competitive acid blocker, in patients with proton pump inhibitor (PPI)-refractory... 
Acid suppression | Potassium-competitive acid blocker | Impedance-pH monitoring | Gastroesophageal reflux disease | Proton pump inhibitor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K+-competitive acid blocker
by Lee, Kyeong-Ryoon and Lee, Hyun A and Lee, Howard and Jang, Seong Bok and Chung, Soo Yong and Yu, Kyung-Sang
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 03/2019, Volume 130, pp. 1 - 10
A physiologically-based pharmacokinetic (PBPK) model was developed for YH4808, a novel potassium-competitive acid blocker, using the SimCYP® Simulator based on... 
Physiologically-based pharmacokinetics | Potassium-competitive acid blocker | Pharmacodynamics | pH-dependent solubility | Pharmacokinetics | Intragastric pH | PERMEABILITY | TISSUE DISTRIBUTION | STRATEGY | PHARMACOLOGY & PHARMACY | SIMULATION | INHIBITION ASSAYS | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action
by Nishida, Haruyuki and Arikawa, Yasuyoshi and Hirase, Keizo and Imaeda, Toshihiro and Inatomi, Nobuhiro and Hori, Yasunobu and Matsukawa, Jun and Fujioka, Yasushi and Hamada, Teruki and Iida, Motoo and Nishitani, Mitsuyoshi and Imanishi, Akio and Fukui, Hideo and Itoh, Fumio and Kajino, Masahiro
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 07/2017, Volume 25, Issue 13, pp. 3298 - 3314
With the aim to find a novel long-lasting potassium-competitive acid blocker (P-CAB) that would perfectly overcome the limitations of proton pump inhibitors... 
Low lipophilicity | H+,K+-ATPase | Potassium-competitive acid blocker | Fluoropyrrole | Long duration of action | LANSOPRAZOLE | CHEMISTRY, MEDICINAL | BREAKTHROUGH | TAK-438 | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | PROTON PUMP INHIBITORS | SUPPRESSION | MEDICINAL CHEMISTRY | PANTOPRAZOLE | GASTRIC (H | GASTROESOPHAGEAL-REFLUX DISEASE | SECRETION | Cell Survival - drug effects | Proton Pump Inhibitors - pharmacology | H(+)-K(+)-Exchanging ATPase - metabolism | Administration, Oral | Humans | Ether-A-Go-Go Potassium Channels - metabolism | Rats | Structure-Activity Relationship | Hep G2 Cells | Dose-Response Relationship, Drug | Ether-A-Go-Go Potassium Channels - antagonists & inhibitors | Pyrroles - pharmacology | Animals | Proton Pump Inhibitors - chemistry | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Dogs | HEK293 Cells | Pyrroles - chemistry | Molecular Structure | Gastric Acid - metabolism | Hydrogen-Ion Concentration | Cytokinins | Dimethylformamide | Chemical tests and reagents | Cytochrome P-450 | Proton pump inhibitors | Permeability | Mass spectrometry | Antacids | High performance liquid chromatography | Adenosine triphosphatase | Lithium compounds
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease
by Kawami, Noriyuki and Hoshino, Shintaro and Hoshikawa, Yoshimasa and Takenouchi, Nana and Umezawa, Mariko and Hanada, Yuriko and Kaise, Mitsuru and Iwakiri, Katsuhiko
Digestion, ISSN 0012-2823, 10/2018, Volume 98, Issue 3, pp. 194 - 200
Background: The present study examined the pathogenesis of potassium-competitive acid blocker (P-CAB)-resistant non-erosive reflux disease (NERD). Methods:... 
Non-erosive reflux disease | Vonoprazan | Impedance-pH monitoring | Helicobacter pylori | Potassium-competitive acid blocker-resistant | RABEPRAZOLE | MANAGEMENT | EFFICACY | RANDOMIZED CLINICAL-TRIAL | SYMPTOMS | GASTROENTEROLOGY & HEPATOLOGY | VS. LANSOPRAZOLE | Proton Pump Inhibitors - pharmacology | Gastroesophageal Reflux - diagnosis | Esophageal pH Monitoring | Gastroesophageal Reflux - pathology | Humans | Middle Aged | Heartburn - diagnosis | Male | Treatment Outcome | Proton Pump Inhibitors - therapeutic use | Gastroesophageal Reflux - complications | Heartburn - etiology | Gastric Acidity Determination | Female | Gastric Acid - metabolism | Gastroesophageal Reflux - drug therapy | Potassium | Drug Resistance | Heartburn - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)
by Otake, Kazuyoshi and Sakurai, Yuuichi and Nishida, Haruyuki and Fukui, Hideo and Tagawa, Yoshihiko and Yamasaki, Hitomi and Karashima, Masatoshi and Otsuka, Keiichi and Inatomi, Nobuhiro
Advances in Therapy, ISSN 0741-238X, 7/2016, Volume 33, Issue 7, pp. 1140 - 1157
Proton pump inhibitors (PPIs) are widely prescribed as first-line therapy for the treatment of acid-related diseases, such as peptic ulcers and... 
Potassium-competitive acid blockers | Vonoprazan | Acid-related diseases | TAK-438 | Rheumatology | Helicobacter pylori eradication | PPI | Internal Medicine | Oncology | Reflux esophagitis | Proton pump inhibitor | Medicine & Public Health | Gastroenterology | Cardiology | Pharmacology/Toxicology | Endocrinology | Lansoprazole | MEDICINE, RESEARCH & EXPERIMENTAL | CYP2C19 GENOTYPE | ANTIBIOTIC-RESISTANCE | PROTON-PUMP INHIBITORS | TRIAL | INTRAGASTRIC PH | GASTROESOPHAGEAL-REFLUX DISEASE | PHARMACOLOGY & PHARMACY | SECRETION | MONOFUMARATE TAK-438 | HELICOBACTER-PYLORI | Gastrointestinal Agents - pharmacology | Pyrroles - pharmacology | Pyrroles - pharmacokinetics | Sulfonamides - therapeutic use | Gastrointestinal Diseases - drug therapy | Humans | Gastrointestinal Agents - therapeutic use | Gastrointestinal Agents - pharmacokinetics | Pyrroles - therapeutic use | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Hydrogen-Ion Concentration | Gastroesophageal reflux | Physiological aspects | Peptic ulcer | Antacids | Genetic polymorphisms | Cytochrome P-450
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium‐competitive acid blocker, in healthy male subjects
by Sunwoo, J and Oh, J and Moon, S. J and Ji, S. C and Lee, S. H and Yu, K.‐S and Kim, H. S and Lee, A and Jang, I.‐J
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 07/2018, Volume 48, Issue 2, pp. 206 - 218
Background: A novel potassium-competitive acid blocker, DWP14012, is in clinical development as a potential alternative to proton pump inhibitors for the... 
BIOMARKERS | ESOMEPRAZOLE | ARTICLE | GASTROESOPHAGEAL-REFLUX DISEASE | PHARMACOLOGY & PHARMACY | VONOPRAZAN | GASTROENTEROLOGY & HEPATOLOGY | INDUCED LIVER-INJURY | Binding, Competitive | Sodium-Potassium-Exchanging ATPase - antagonists & inhibitors | Double-Blind Method | Esomeprazole - administration & dosage | Administration, Oral | Esomeprazole - pharmacokinetics | Humans | Middle Aged | Anti-Ulcer Agents - adverse effects | Esomeprazole - adverse effects | Male | Healthy Volunteers | Anti-Ulcer Agents - administration & dosage | Anti-Ulcer Agents - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Placebos | Adult | Pharmacokinetics | Helicobacter infections | Proton pump inhibitors | Dosage and administration | Safety and security measures | Antacids | Urine | Pharmacodynamics | Toxicity | Secretion | Liver | Medical treatment | MiRNA | Pharmacology | Omeprazole | Acids | Ribonucleic acids | Helicobacter pylori | pH | Safety | Potassium | Active control | Gastric juice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease
by Okuyama, Masatsugu and Nakahara, Kenichi and Iwakura, Narika and Hasegawa, Tomoki and Oyama, Maizumi and Inoue, Ayumi and Ishizu, Hirotaka and Satoh, Hiroshi and Fujiwara, Yasuhiro
Digestion, ISSN 0012-2823, 07/2017, Volume 95, Issue 4, pp. 281 - 287
Background/Aims: Approximately 20-40% of patients with gastroesophageal reflux disease (GERD) are refractory to proton pump inhibitor (PPI) treatment. The... 
Potassium-competitive acid blocker | Vonoprazan | Drug therapy | Proton pump inhibitor-refractory gastroesophageal reflux disease | EFFICACY | ATHENS-INSOMNIA-SCALE | IMPEDANCE | SLEEP DISTURBANCES | SYMPTOMS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Middle Aged | Male | Proton Pump Inhibitors - therapeutic use | Gastroesophageal Reflux - complications | Sulfonamides - therapeutic use | Treatment Failure | Aged, 80 and over | Sleep Wake Disorders - prevention & control | Female | Aged | Gastroesophageal Reflux - drug therapy | Pyrroles - therapeutic use | Sleep Wake Disorders - etiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2′-piperidin)-1-ones as potassium-competitive acid blockers
by Imaeda, Toshihiro and Ono, Koji and Nakai, Kazuo and Hori, Yasunobu and Matsukawa, Jun and Takagi, Terufumi and Fujioka, Yasushi and Tarui, Naoki and Kondo, Mitsuyo and Imanishi, Akio and Inatomi, Nobuhiro and Kajino, Masahiro and Itoh, Fumio and Nishida, Haruyuki
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 07/2017, Volume 25, Issue 14, pp. 3719 - 3735
With the aim to discover a gastric antisecretory agent more potent than the existing proton pump inhibitors, novel 3,4-dihydro-1... 
Potassium-competitive acid blockers | H+,K+-ATPase | Docking analysis | 3,4-Dihydro-1H-spiro[naphthalene-2,2′-piperidin]-1-one derivatives | S-Enantiomer | CHEMISTRY, MEDICINAL | GASTROESOPHAGEAL-REFLUX DISEASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | 3,4-Dihydro-1H-spirotnaphthalene-2,2 '-piperidin]-1-one derivatives | Histamine - toxicity | Potassium - metabolism | Area Under Curve | Half-Life | Structure-Activity Relationship | Gastric Mucosa - metabolism | Gastric Acid - secretion | H(+)-K(+)-Exchanging ATPase - chemistry | Spiro Compounds - chemical synthesis | Gastric Mucosa - drug effects | Inhibitory Concentration 50 | Piperidines - pharmacokinetics | Proton Pump Inhibitors - chemical synthesis | Drug Evaluation, Preclinical | Binding Sites | Spiro Compounds - chemistry | Naphthalenes - chemistry | Piperidines - chemistry | H(+)-K(+)-Exchanging ATPase - metabolism | Rats | Piperidines - chemical synthesis | Spiro Compounds - pharmacokinetics | Potassium - chemistry | Administration, Intravenous | Animals | Proton Pump Inhibitors - chemistry | Proton Pump Inhibitors - pharmacokinetics | Gastric Mucosa - secretion | ROC Curve | Molecular Docking Simulation | Gastric Acid - metabolism | Antacids | Resveratrol | Gastroesophageal reflux | Dimethylformamide | Chemical tests and reagents | Lithium compounds | Cytokinins | Histamine | Proton pump inhibitors | Metallocenes | Derivatives (Financial instruments) | High performance liquid chromatography | Adenosine triphosphatase
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Exploration of pyrrole derivatives to find an effective potassium-competitive acid blocker with moderately long-lasting suppression of gastric acid secretion
by Nishida, Haruyuki and Fujimori, Ikuo and Arikawa, Yasuyoshi and Hirase, Keizo and Ono, Koji and Nakai, Kazuo and Inatomi, Nobuhiro and Hori, Yasunobu and Matsukawa, Jun and Fujioka, Yasushi and Imanishi, Akio and Fukui, Hideo and Itoh, Fumio
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 07/2017, Volume 25, Issue 13, pp. 3447 - 3460
With the aim to discover a novel excellent potassium-competitive acid blocker (P-CAB) that could perfectly overcome the limitations of proton pump inhibitors... 
Potassium-competitive acid blocker | Transfer behavior to the stomach | Rapid onset | Moderately long-lasting acid suppression | LANSOPRAZOLE | CHEMISTRY, MEDICINAL | BREAKTHROUGH | SAFETY | BIOCHEMISTRY & MOLECULAR BIOLOGY | TAK-438 VONOPRAZAN | OMEPRAZOLE | CHEMISTRY, ORGANIC | PROTON PUMP INHIBITORS | PHARMACODYNAMICS | PHARMACOKINETICS | GASTROESOPHAGEAL-REFLUX DISEASE | TOLERABILITY | Potassium - metabolism | Proton Pump Inhibitors - pharmacology | H(+)-K(+)-Exchanging ATPase - metabolism | Administration, Oral | Humans | Rats | Male | Structure-Activity Relationship | Rats, Sprague-Dawley | Dose-Response Relationship, Drug | Pyrroles - pharmacology | Animals | Proton Pump Inhibitors - chemistry | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Pyrroles - chemistry | Molecular Structure | Gastric Acid - metabolism | Thiols | Chemical tests and reagents | Ionization | Cytochrome P-450 | Dimethyl sulfoxide | Physiological aspects | Proton pump inhibitors | Fluorides | Mass spectrometry | Antacids | High performance liquid chromatography | Lithium compounds
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Synthetic Studies of Vonoprazan Fumarate, a Novel Potassium Competitive Acid Blocker (P-CAB)
by Arikawa, Y
JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, ISSN 0037-9980, 03/2019, Volume 77, Issue 3, pp. 254 - 261
The major target in the pharmacological treatment for acid related diseases is the gastric proton pump enzyme H+,K+-ATPase which is responsible for acid... 
H+,K+-ATPase | potassium-competitive acid blocker (P-CAB) | TAK-438 | ligand-lipophilicity efficiency (LLE) | CHEMISTRY, ORGANIC | acid-related diseases | Vonoprazan Fumarate (Takecab (R)) | high through-put screening (HTS)
Journal Article
Details down arrow
14. Full Text Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects
by Kim, Eunwoo and Kim, Anhye and Yi, Sojeong and Kim, Yu Kyong and Jang, Seong Bok and Byun, Hae Mi and Yoon, Seo Hyun and Cho, Joo-Youn and Jang, In-Jin and Yu, Kyung-Sang and Lee, SeungHwan
European Journal of Clinical Pharmacology, ISSN 0031-6970, 10/2018, Volume 74, Issue 10, pp. 1261 - 1272
YH4808 is a potassium-competitive acid blocker, developed for the treatment of acid-related disorders. Two clinical studies in healthy male subjects were... 
Biomedicine | Food effect | Pharmacology/Toxicology | Pharmacokinetics | YH4808 | Potassium competitive acid blocker | GASTROESOPHAGEAL-REFLUX DISEASE | PHARMACOLOGY & PHARMACY | DRUG ABSORPTION | Potassium - metabolism | Dietary Fats - metabolism | Esomeprazole - analogs & derivatives | Esomeprazole - administration & dosage | Administration, Oral | Area Under Curve | Esomeprazole - pharmacokinetics | Food-Drug Interactions | Humans | Esomeprazole - adverse effects | Biological Availability | Male | Healthy Volunteers | Dose-Response Relationship, Drug | Antacids - pharmacokinetics | Antacids - adverse effects | Adult | Female | Gastric Acid - metabolism | Gastroesophageal Reflux - drug therapy | Antacids - administration & dosage | Medicine, Experimental | Medical research | Dosage and administration | Antacids | Dosing | Parameter estimation | Randomization | Acids | Pharmacology | Exposure | Potassium | Steady state | Food
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors
by Yamashita, Hiroshi and Kanamori, Atsushi and Kano, Chise and Hashimura, Hiroki and Matsumoto, Kei and Tsujimae, Masahiro and Yoshizaki, Tetsuya and Momose, Kenji and Obata, Daisuke and Eguchi, Takaaki and Fujita, Mikio and Okada, Akihiko
Digestion, ISSN 0012-2823, 08/2017, Volume 96, Issue 1, pp. 52 - 59
Background/Aim: The effects of vonoprazan and proton pump inhibitors (PPIs) in patients with reflux esophagitis (RE) have not yet been compared using... 
Potassium-competitive acid blockers | Proton pump inhibitors | pH <4 holding time rate | Vonoprazan | Reflux esophagitis | Refractory reflux esophagitis | ESOMEPRAZOLE | LANSOPRAZOLE | RABEPRAZOLE | CLEARANCE | GENOTYPE | CYP2C19 | GASTROESOPHAGEAL-REFLUX | DISEASE | ERADICATION | GASTROENTEROLOGY & HEPATOLOGY | HELICOBACTER-PYLORI | Potassium - metabolism | Proton Pump Inhibitors - pharmacology | Esophageal pH Monitoring | Humans | Middle Aged | Male | Gastric Mucosa - metabolism | Gastric Acid - secretion | Time Factors | Gastric Mucosa - drug effects | Aged, 80 and over | Female | Pyrroles - therapeutic use | Esophagitis, Peptic - complications | Manometry | Esophagitis, Peptic - microbiology | Drug Resistance - drug effects | Drug Substitution - methods | Electric Impedance | Proton Pump Inhibitors - therapeutic use | Sulfonamides - pharmacology | Esophageal Mucosa - drug effects | Esophagitis, Peptic - drug therapy | Pyrroles - pharmacology | Sulfonamides - therapeutic use | Gastric Mucosa - secretion | Cytochrome P-450 CYP2C19 - metabolism | Aged | Esophageal Mucosa - pathology | Helicobacter pylori - isolation & purification | Helicobacter Infections - microbiology | Hydrogen-Ion Concentration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Vonoprazan fumarate, a novel potassiumcompetitive acid blocker, in the management of gastroesophageal reflux disease: Safety and clinical evidence to date
by Sugano, Kentaro
Therapeutic Advances in Gastroenterology, ISSN 1756-283X, 01/2018, Volume 11
Potassium-competitive acid blocker | Vonoprazan | Safety | Gastroesophageal reflux disease | Proton pump inhibitor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs
by Kogame, Akifumi and Takeuchi, Toshiyuki and Nonaka, Masami and Yamasaki, Hitomi and Kawaguchi, Naohiro and Bernards, Ai and Tagawa, Yoshihiko and Morohashi, Akio and Kondo, Takahiro and Moriwaki, Toshiya and Asahi, Satoru
Xenobiotica, ISSN 0049-8254, 03/2017, Volume 47, Issue 3, pp. 255 - 266
1. Following oral administration of [ 14 C]TAK-438, the radioactivity was rapidly absorbed in rats and dogs. The apparent absorption of the radioactivity was... 
LC/MS | pharmacokinetics | potassium-competitive acid blocker | metabolite profiling | ANIMALS | DISEASES | PROTON PUMP INHIBITORS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MONOFUMARATE TAK-438 | Tissue Distribution | Pyrroles - metabolism | Animals | Proton Pump Inhibitors - pharmacokinetics | Pyrroles - pharmacokinetics | Dogs | Proton Pump Inhibitors - metabolism | Sulfonamides - metabolism | Rats | Bile - metabolism | Feces | Sulfonamides - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights